Oliver Lagore Vanvalin Investment Group Takes Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Oliver Lagore Vanvalin Investment Group purchased 2,298 shares of Intuitive Surgical, valued at approximately $1,138,000, during the second quarter.
• Institutional investors and hedge funds hold 83.64% of Intuitive Surgical stock, with several large investors, including Vanguard Group and Wellington Management, increasing their stakes in the company.
• Intuitive Surgical recently posted earnings that beat analysts' expectations, reporting $2.19 EPS and a revenue increase of 21.4% compared to the previous year.

Oliver Lagore Vanvalin Investment Group purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,298 shares of the medical equipment provider's stock, valued at approximately $1,138,000.

Several other institutional investors have also recently added to or reduced their stakes in ISRG. Vanguard Group Inc. raised its holdings in shares of Intuitive Surgical by 1.4% during the first quarter. Vanguard Group Inc. now owns 32,665,531 shares of the medical equipment provider's stock worth $16,178,258,000 after purchasing an additional 453,335 shares during the period. Invesco Ltd. grew its position in Intuitive Surgical by 1.7% in the 1st quarter. Invesco Ltd. now owns 4,219,974 shares of the medical equipment provider's stock valued at $2,090,027,000 after buying an additional 71,794 shares in the last quarter. Northern Trust Corp grew its position in Intuitive Surgical by 0.3% in the 1st quarter. Northern Trust Corp now owns 3,631,281 shares of the medical equipment provider's stock valued at $1,798,465,000 after buying an additional 11,988 shares in the last quarter. Wellington Management Group LLP grew its position in Intuitive Surgical by 15.0% in the 1st quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider's stock valued at $1,732,975,000 after buying an additional 457,080 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Intuitive Surgical during the 1st quarter valued at about $1,715,899,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. BTIG Research upped their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Wells Fargo & Company upped their price objective on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research note on Wednesday, July 23rd. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Finally, Piper Sandler reissued an "overweight" rating and issued a $595.00 price target (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Stock Performance

NASDAQ:ISRG traded up $4.90 on Tuesday, hitting $449.45. 780,536 shares of the stock were exchanged, compared to its average volume of 2,041,789. The stock has a market capitalization of $161.12 billion, a price-to-earnings ratio of 62.67, a P/E/G ratio of 4.60 and a beta of 1.61. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00. The company's 50-day moving average price is $475.20 and its 200 day moving average price is $502.92.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same period in the prior year, the business posted $1.78 EPS. Intuitive Surgical's revenue was up 21.4% on a year-over-year basis. As a group, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In related news, Director Amy L. Ladd sold 335 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total value of $147,631.15. Following the transaction, the director owned 739 shares in the company, valued at approximately $325,669.91. This trade represents a 31.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary S. Guthart sold 29,360 shares of the business's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $472.49, for a total value of $13,872,306.40. Following the sale, the insider owned 19,827 shares in the company, valued at approximately $9,368,059.23. This trade represents a 59.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,224 shares of company stock valued at $21,716,492. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.